Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OSI oncology business

Executive Summary

Former Pharmacia Group VP-Global Prescription Business Gabriel Leung named OSI oncology president. Leung's initial responsibilities will include re-launches for Novantrone (licensed from Amgen) and Gelclair (acquired through Cell Pathways acquisition) (1"The Pink Sheet" May 19, p. 7)...

You may also be interested in...



OSI Confident On Tarceva After Iressa Approval; Brain Cancer Is Back-Up Plan

OSI Pharmaceuticals is confident about Tarceva's prospects for FDA clearance based on the recent Subpart H approval of AstraZeneca's Iressa

Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities

Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel